We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics - An LGC Company


Illumina develops, manufactures and markets integrated systems for the analysis of genetic variations and biological ... read more Featured Products: More products

Download Mobile App

Mutation Identified That Reduces Type II Diabetes Risk

By LabMedica International staff writers
Posted on 12 May 2015
Print article
HumanExome BeadChip v1.2
HumanExome BeadChip v1.2 (Photo courtesy of Illumina)
A mutation in the GLP1R (glucagon-like peptide 1 receptor) gene was found to reduce the risk of developing Type II diabetes by nearly 14%.

The protein encoded by the chromosome six GLP1R gene is a member of the glucagon receptor family of G protein-coupled receptors. GLP1R binds specifically to glucagon-like peptide-1 (GLP1) and has much lower affinity for related peptides such as the gastric inhibitory polypeptide and glucagon. GLP1R is known to be expressed in pancreatic beta cells where it stimulates the adenylyl cyclase pathway, which results in increased insulin synthesis and release of insulin. GLP1R is also expressed in the brain where it is involved in the control of appetite.

Investigators at Cedars-Sinai Medical Center (Los Angeles, CA, USA) and colleagues in the Cohorts for Heart and Aging Research in Genomic Epidemiology international consortium used Illumina (San Diego, CA, USA) HumanExome BeadChip technology to analyze the genes of 81,000 people who did not have Type II diabetes and then compared their genetic information to that of 16,000 diabetics.

The HumanExome BeadChip covers functional exonic variants selected from over 12,000 individual exome and whole-genome sequences. The exonic content consists of more than 240,000 markers representing diverse populations, including European, African, Chinese, and Hispanic individuals, and a range of common conditions, such as Type II diabetes, cancer, metabolic, and psychiatric disorders.

Results of the exome mapping study were published in the January 29, 2015, online edition of the journal Nature Communications. They revealed that a mutation in the GLP1R gene appeared to decrease the risk of developing Type II diabetes by about 14%.

Senior author Dr. Mark O. Goodarzi, professor of endocrinology at Cedars-Sinai Medical Center, said, "We have a wonderful opportunity to personalize the treatment and prevention of this chronic disease. Identification of genes that influence the risk of diabetes is going to open new frontiers in diabetes drug development. The mutation we discovered may prevent certain people from developing diabetes, but it does not appear to affect their risk of becoming obese or their body mass index."

Related Links:

Cedars-Sinai Medical Center

Gold Supplier
Renin Control
Lumipulse Renin Control
Total Immunoglobulin E (IgE) Test
ALLERgen Total-IgE ELISA Kit
Auto Mass Spectrometry Microbial Identification System
Microbe LW MS-5000
Rupture of Fetal Membranes Test
AmniSure ROM Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
Click here to Register




view channel
Image: Scientists have won USD 9.5 million to study emerging pathogens (Photo courtesy of Pexels)

Study of Emerging Pathogens to Better Understand Influenza-Antibody Interactions Could Improve Diagnostics

Outbreaks of Avian influenza have occurred around the world for over a century. The highly pathogenic H5N1 virus which was first identified in 1996 can lead to severe disease and has a high fatality rate... Read more


view channel
Image: Medical illustration of Carbapenem-resistant Enterobacteriacea (Photo courtesy of CDC, Stephanie Rossow)

Breakthrough Test Enables Targeted Antibiotic Therapy for Various Enterobacter Species

Bacteria of the Enterobacter genus are considered to be the most dangerous bacteria linked to hospital infections across the world. Some of their representatives demonstrate high resistance to commonly-used... Read more


view channel
Image: Flexible copper sensor made cheaply from ordinary materials (Photo courtesy of University of São Paulo)

Low-Cost Portable Sensor Detects Heavy Metals in Sweat

Heavy metals like lead and cadmium can be found in batteries, cosmetics, food and many other things that have become a part of daily life. However, they become toxic if they accumulate in the human body... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.